Pfizer Inc. has announced that the European Commission has approved Besponsa (inotuzumab ozogamicin) as monotherapy for the treatment of adults...
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Pfizer�s Besponsa (inotuzumab ozogamicin) to...
The National Institute for Health and Care Excellence (NICE) has published draft guidance not recommending Pfizer’s Besponsa (inotuzumab ozogamicin) to...
Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL.
Pfizer Inc. announced the discontinuation of a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of...
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...
Pfizer has announced the publication of findings from the Phase III INO-VATE ALL study of PF 5208773 (inotuzumab ozogamicin) in...
Pfizer announced that the Phase III study investigating the treatment of inotuzumab ozogamicin met its first primary endpoint of demonstrating...
Following a successful appeal by Pfizer the National Institute for Health and Care Excellence (NICE) will reassess Besponsa (inotuzumab ozogamicin) as...
BESPONSA is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph + ) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI).